RETRACTION: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic bod...
RETRACTION: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
About this item
Full title
Author / Creator
Publisher
London: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
SummaryBackgroundThere is paucity of investigations into immunotherapy or targeted therapy for postoperative locally recurrent pancreatic cancer. We aimed to assess the efficacy of stereotactic body radiotherapy (SBRT) plus pembrolizumab and trametinib in these patients. MethodsIn this open-label, randomised, controlled, phase 2 study, participants...
Alternative Titles
Full title
RETRACTION: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2556818397
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2556818397
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(21)00286-2
